InnoCare Pharma, a leading biopharmaceutical company, announced that Hibruka (orelabrutinib) has been approved by the Health Sciences Authority (HSA) of Singapore for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (r/r MCL).
Dr. Jasmine Cui, co-founder, chairwoman and CEO of InnoCare said,
